Definitive Healthcare Corp. (DH) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Definitive Healthcare Corp. (DH) trades at $0.718 with AI Score 20/100 (Grade F). Definitive Healthcare Corp. Market cap: $75.8M, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: May 7, 2026DH stock analysis for 2026: Analysts have set a consensus price target of $3.50 for Definitive Healthcare Corp., suggesting 387.5% upside from the current price of $0.72. The AI MoonshotScore is 20/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
DH: 1/3 scored disciplines lean bearish. Dominant signal: Momentum weak.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Definitive Healthcare Corp. (DH) Healthcare & Pipeline Overview
Definitive Healthcare Corp. delivers commercial intelligence to the healthcare sector in the United States, equipping clients with data-driven insights for product development, marketing strategies, and sales execution. Its comprehensive platform, featuring 16 intelligence modules, caters to biopharmaceutical, medical device, and healthcare IT companies.
What Is the Investment Thesis for DH?
Definitive Healthcare Corp. operates in the growing healthcare commercial intelligence market. The company's platform, with its 16 intelligence modules, offers a comprehensive solution for clients across the healthcare spectrum. However, the company's negative profit margin of -57.5% raises concerns about its profitability. Growth catalysts include expanding its customer base and enhancing its product offerings. The company's high beta of 1.60 suggests higher volatility compared to the broader market. Investors should carefully consider the company's financial performance and market dynamics before making investment decisions. Key value drivers include increasing subscription revenue and expanding into new market segments.
Based on FMP financials and quantitative analysis
DH Key Highlights
Definitive Healthcare Corp. operates in the healthcare commercial intelligence sector, providing data and analytics solutions.
- The company's platform offers 16 intelligence modules covering areas like sales, marketing, and product development.
- Definitive Healthcare serves a diverse range of customers, including biopharmaceutical, medical device, and healthcare IT companies.
- The company's gross margin stands at 75.9%, indicating strong pricing power and efficient cost management.
- Definitive Healthcare Corp. has a market capitalization of $75.8M, reflecting its current market valuation.
Who Are DH's Competitors?
DH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CCLD CareCloud, Inc. | $2.64 | +1.93% | $112M | 69 |
| AUGX Augmedix, Inc. | $2.35 | -0.21% | $116M | 58 |
| VRHI Veri Medtech Holdings Inc. | $2.35 | +0.00% | $46.9M | 67 |
| ONVVF Oneview Healthcare PLC | $0.16 | +0.00% | $123M | 60 |
| AIRDF Rocket Doctor AI Inc. | $0.44 | -2.99% | $42.4M | 56 |
| OPRX OptimizeRx Corporation | $8.08 | +0.87% | $152M | 87 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.1M | 67 |
| VPAHF Volpara Health Technologies Limited | $0.74 | +36.63% | $188M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DH's Key Strengths?
Comprehensive healthcare commercial intelligence platform.
- Diverse customer base across the healthcare ecosystem.
- Established presence in the United States.
- Strong gross margin of 75.9%.
What Are DH's Weaknesses?
Negative profit margin of -57.5%.
- High beta of 1.60, indicating higher volatility.
- Reliance on the U.S. market.
- Limited brand recognition outside the healthcare sector.
What Could Drive DH Stock Higher?
Expansion of product offerings with new intelligence modules.
- Strategic partnerships and acquisitions to expand capabilities and market reach.
- Penetration of new customer segments within the healthcare ecosystem.
What Are the Key Risks for DH?
Financial-distress signal — its Altman Z-Score of -3.23 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-67.1%) — the business is not currently generating profit on shareholder capital.
- Increasing competition in the healthcare information services industry.
- Changes in healthcare regulations and policies.
- Economic downturn affecting healthcare spending.
- Data security and privacy concerns.
What Are the Growth Opportunities for DH?
- Expansion into New Geographic Markets: Definitive Healthcare has the opportunity to expand its presence beyond the United States and enter new geographic markets. The global healthcare analytics market is estimated to reach $75 billion by 2027, presenting significant growth potential for the company. By establishing a presence in key international markets, Definitive Healthcare can diversify its revenue streams and capitalize on the growing demand for healthcare commercial intelligence worldwide. This expansion could involve strategic partnerships, acquisitions, or organic growth initiatives, with a timeline of 3-5 years.
- Enhancement of Product Offerings: Definitive Healthcare can further enhance its product offerings by developing new intelligence modules and integrating advanced analytics capabilities into its platform. This could involve incorporating artificial intelligence and machine learning technologies to provide more predictive and personalized insights to its clients. By continuously innovating and expanding its product portfolio, Definitive Healthcare can strengthen its competitive position and attract new customers. The timeline for these enhancements is estimated at 2-3 years.
- Strategic Partnerships and Acquisitions: Definitive Healthcare can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. This could involve partnering with complementary technology providers or acquiring companies with specialized expertise in areas such as healthcare data analytics or market research. By leveraging the strengths of its partners and acquired companies, Definitive Healthcare can accelerate its growth and enhance its value proposition. The timeline for these partnerships and acquisitions is ongoing.
- Penetration of New Customer Segments: Definitive Healthcare can target new customer segments within the healthcare ecosystem, such as pharmaceutical companies, insurance providers, and government agencies. These segments represent significant growth opportunities for the company, as they increasingly rely on data-driven insights to make informed decisions. By tailoring its solutions to meet the specific needs of these customer segments, Definitive Healthcare can expand its customer base and increase its revenue. The timeline for this penetration is estimated at 3-5 years.
- Leveraging Data Monetization Opportunities: Definitive Healthcare can explore opportunities to monetize its extensive healthcare data assets by offering customized data products and services to its clients. This could involve providing access to anonymized patient data for research purposes or developing specialized data reports and dashboards for specific industry segments. By leveraging its data assets, Definitive Healthcare can generate new revenue streams and enhance its profitability. The timeline for these monetization opportunities is estimated at 2-3 years.
What Are DH's Competitive Advantages?
- Proprietary data assets and analytics platform.
- Comprehensive suite of 16 intelligence modules.
- Established relationships with key players in the healthcare ecosystem.
What Does DH Do?
Founded in 2011 and headquartered in Framingham, Massachusetts, Definitive Healthcare Corp. has emerged as a key player in the healthcare commercial intelligence sector. The company provides data and analytics solutions to healthcare providers and organizations across the United States. Its platform offers a suite of 16 intelligence modules designed to support various functional areas, including sales, marketing, clinical research, product development, strategy, talent acquisition, and physician network management. These modules provide detailed information on healthcare providers and their activities, enabling clients to make informed decisions across their operations. Definitive Healthcare's solutions assist clients in areas ranging from identifying market opportunities and developing new products to optimizing go-to-market strategies and enhancing sales and marketing effectiveness. The company serves a diverse range of customers, including biopharmaceutical and medical device companies, healthcare information technology companies, healthcare providers, and other organizations within the healthcare ecosystem, such as staffing and commercial real estate companies, financial institutions, and other diversified entities.
What Products and Services Does DH Offer?
- Provides healthcare commercial intelligence in the United States.
- Offers a platform with 16 intelligence modules covering various functional areas.
- Serves biopharmaceutical and medical device companies.
- Supports healthcare information technology companies.
- Caters to healthcare providers.
- Assists staffing and commercial real estate companies in the healthcare ecosystem.
- Provides data to financial institutions.
How Does DH Make Money?
- Subscription-based access to its healthcare commercial intelligence platform.
- Provides data and analytics solutions to healthcare providers and organizations.
- Offers customized data products and services to clients.
What Industry Does DH Operate In?
Definitive Healthcare Corp. operates within the healthcare information services industry, a sector experiencing growth due to the increasing demand for data-driven insights in healthcare decision-making. The market is competitive, with companies offering various solutions for healthcare data analytics and commercial intelligence. Definitive Healthcare differentiates itself through its comprehensive platform and focus on providing actionable insights to its clients. The healthcare analytics market is projected to continue growing, driven by factors such as the increasing adoption of electronic health records, the rise of value-based care, and the growing need for healthcare organizations to improve operational efficiency and patient outcomes.
Who Are DH's Key Customers?
- Biopharmaceutical companies
- Medical device companies
- Healthcare information technology companies
- Healthcare providers
- Staffing and commercial real estate companies
Company Profile
Definitive Healthcare Corp. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Framingham, US. The company is led by CEO Kevin D. Coop. DH has traded publicly since 2021.
Key Financial Metrics
Return on equity for Definitive Healthcare Corp. stands at -67.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.1%, showing how much profit it generates from its asset base. Its free cash flow yield is 46.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.66 indicates the company holds enough short-term assets to cover its near-term obligations.
DH Valuation & Market Position
With a $75.8M market cap, Definitive Healthcare Corp. sits in the micro-cap segment of the market. Relative to its peer group, DH's quantitative score of 20/100 is below the peer average of 62/100.
Quarterly Financial Performance: Definitive Healthcare Corp.
Revenue for Definitive Healthcare Corp. came in at $55.2M during Q2 2026, a 1.3% contraction versus the preceding quarter. The company recorded a net loss of $5.4M, with diluted EPS of $-0.05. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, DH averaged $-0.40 in diluted EPS.
Financial Health
Definitive Healthcare Corp.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -3.23 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Definitive Healthcare Corp. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 45.4% above estimates on average.
Forward Outlook
Wall Street analysts project Definitive Healthcare Corp. revenue of about $223.4M for fiscal 2026, with EPS near $0.18. The estimate reflects 5 contributing analysts.
DH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future performance, indicating that key stakeholders believe in its growth potential.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments and their impact on healthcare analytics.
- Analysts have noted increased demand for data-driven healthcare solutions, positioning Definitive Healthcare favorably in a growing market.
- Recent partnerships with major healthcare providers indicate strong market validation and an expanding customer base.
Bear Case
- Some community members express concerns over competition in the healthcare data space, fearing that larger players may overshadow Definitive Healthcare.
- Recent earnings reports highlighted challenges in scaling operations, raising questions about the company's ability to manage growth effectively.
- Market sentiment has been cautious due to broader economic uncertainties, which could impact healthcare spending and investment in analytics.
- There is ongoing skepticism regarding the sustainability of recent growth trends, with some analysts warning of potential market corrections.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $55M | -$5M | -$0.05 |
| Q1 2026 | $56M | -$139M | -$1.32 |
| Q4 2025 | $62M | -$9M | -$0.09 |
| Q3 2025 | $60M | -$15M | -$0.14 |
Based on FMP financials and quantitative analysis
DH Latest News
-
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga · Aug 10, 2026
DH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DH.
Price Targets
Consensus target: $3.50
DH MoonshotScore
What does this score mean?
The MoonshotScore rates DH 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Kevin D. Coop
Unknown
Information about Kevin D. Coop's background is not available in the provided data. Without additional context, it is impossible to provide details about his career history, education, previous roles, or credentials. More data is needed to complete this section with accurate and relevant information.
Track Record: Information about Kevin D. Coop's track record is not available in the provided data. Without additional context, it is impossible to provide details about his key achievements, strategic decisions, or company milestones under his leadership. More data is needed to complete this section with accurate and relevant information.
Common Questions About DH (Healthcare)
What does the AI Score mean for DH?
DH holds an AI Score of 20/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Definitive Healthcare Corp. provides healthcare commercial intelligence in the United States, offering solutions that help clients with product development, go-to-market planning, and sales …
What does Definitive Healthcare Corp. do?
Definitive Healthcare Corp. provides healthcare commercial intelligence in the United States. Its platform offers 16 intelligence modules that cover functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management.
What do analysts say about DH stock?
Analyst consensus on Definitive Healthcare Corp. (DH) is not available within the provided data. Without this information, it is impossible to provide a summary of analyst ratings, price targets, or investment recommendations. Investors should consult reputable financial news sources and analyst reports for up-to-date information on DH stock. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, are necessary for a comprehensive analysis.
What are the main risks for DH?
Definitive Healthcare Corp. faces several risks, including increasing competition in the healthcare information services industry, which could pressure pricing and market share. Changes in healthcare regulations and policies could also impact the demand for its services. An economic downturn could reduce healthcare spending, affecting the company's revenue.
What are the key factors to evaluate for DH?
Definitive Healthcare Corp. (DH) holds an AI score of 20/100 (low). Analysts target $3.50 (+387%). operates in the growing healthcare commercial intelligence market. Not financial advice.
How frequently does DH data refresh on this page?
DH's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven DH's recent stock price performance?
Definitive Healthcare Corp. (DH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive healthcare commercial intelligence platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DH overvalued or undervalued right now?
Definitive Healthcare Corp. (DH) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $3.50 (+387%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research DH before investing?
Before investing in Definitive Healthcare Corp. (DH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited, impacting the depth of analysis.
- CEO background information is unavailable.